News
Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback